Semax vs Dihexa
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: SEMAX, Heptapeptide SEMAX
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia in the 1980s as an analog of the ACTH(4-10) fragment, with a Pro-Gly-Pro tail added to resist breakdown. It is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the ACTH fragment without the parent hormone's cortisol-raising activity. It is used clinically and registered in Russia (including for ischemic stroke and cognitive disorders) but is not approved by the FDA or EMA, and Western evidence is limited.
Also: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin IV, engineered at Washington State University to be orally active and to cross into the brain. The pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. The reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and a foundational 2012 biochemistry paper describing its target was later retracted.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Semax has stronger research evidence (Human Trials) compared to Dihexa (Animal Studies).
Detailed Comparison
| Attribute | Semax | Dihexa |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semax is derived from ACTH(4-10) but, unlike ACTH, does not stimulate the adrenal or cortisol axis; its main documented action is upregulating brain-derived neurotrophic factor (BDNF) and its receptor TrkB, especially in the hippocampus. In rats, a single dose increases BDNF protein and mRNA and raises TrkB phosphorylation, activating growth and survival pathways (such as MAPK/ERK and PI3K/Akt) that support neuron health and plasticity. It also modulates dopamine and serotonin signaling and influences genes tied to the immune and vascular response after brain ischemia. The combined effect in animal models is neuroprotection against insults like reduced blood flow and oxidative stress, plus enhanced learning and memory. The Pro-Gly-Pro extension makes it more stable than the bare ACTH(4-10) sequence, which is partly why it stays active intranasally. | Dihexa is derived from angiotensin IV, a fragment of the renin-angiotensin system that has long been linked to memory in animal work. The leading hypothesis is that it acts on the hepatocyte growth factor (HGF) and its receptor c-Met, a growth-factor system that drives the formation of new dendritic spines and synapses. In cultured hippocampal neurons, dihexa and related angiotensin IV analogs increase spine density, and that effect disappears when the HGF/c-Met system is blocked, which is the main evidence the pathway matters. It is worth being blunt that the exact molecular interaction has been contested, since the original paper proposing direct HGF binding was retracted, so the mechanism is best treated as a working hypothesis rather than settled fact. |
| Common Dosing | 200-600 mcg intranasal daily 1-3x daily, intranasal | 5-20 mg oral or sublingual daily Once daily, effects can last up to 10 days |
| Administration | Intranasal spray (most common) | Oral, sublingual, or intranasal |
| Typical Duration | 10-30 days typical | Cycles of 2-4 weeks |
| Best Time to Take | Morning or early afternoon | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The mechanistic core is well documented preclinically: Dolotov et al. (2006, Brain Research) showed a single intranasal Semax dose raised hippocampal BDNF protein, TrkB phosphorylation, and BDNF and TrkB mRNA in rats, alongside improved learned behavior. Additional rat work shows neuroprotection and changes in immune- and vascular-related gene expression after experimental stroke. Human clinical use is real but the published trials are mostly Russian-language, small, and frequently non-randomized or open-label: studies in acute ischemic-stroke patients reported faster recovery of neurological function, and a 2018 study reported increased plasma BDNF with improvements on disability and motor scales. These results are promising but methodologically weaker than Western regulatory-grade trials and have not been replicated in large independent Western studies. Honest summary: solid animal mechanistic data and decades of Russian clinical use, but the human cognitive and stroke claims rest on small, mostly non-randomized studies and are not validated by FDA or EMA-grade trials. | The published evidence on dihexa is entirely preclinical. Harding, McCoy and colleagues at Washington State University reported that metabolically stabilized angiotensin IV analogs, including dihexa, restored cognition in scopolamine-impaired and aged rats and stimulated synaptogenesis in cultured neurons (J Pharmacol Exp Ther, 2012 and follow-ups). A 2014 study tied the procognitive and synaptogenic effects of these analogs to the HGF/c-Met system. There are no registered human clinical trials and no published human safety or pharmacokinetic data, so dosing, long-term safety and whether any of the rodent benefit translates to people are all unknown. One important caveat for anyone reading the primary literature: the 2012 paper that first proposed dihexa as an HGF/Met modifier was formally retracted in 2024, which weakens the strongest mechanistic claim. Treat dihexa as an interesting research molecule with promising animal data and a notable evidence gap, not as a proven cognitive enhancer. |
Frequently Asked Questions: Semax vs Dihexa
What is the difference between Semax and Dihexa?
Semax is a cognitive peptide that semax is a synthetic heptapeptide (met-glu-his-phe-pro-gly-pro) developed in russia in the 1980s as an analog of the acth(4-10) fragment, with a pro-gly-pro tail added to resist breakdown. it is researched and used as a neuroprotective and nootropic agent, typically intranasally, and keeps the cognitive and neurotrophic effects of the acth fragment without the parent hormone's cortisol-raising activity. it is used clinically and registered in russia (including for ischemic stroke and cognitive disorders) but is not approved by the fda or ema, and western evidence is limited. Dihexa is a cognitive peptide that dihexa (n-hexanoic-tyr-ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin iv, engineered at washington state university to be orally active and to cross into the brain. the pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. the reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and a foundational 2012 biochemistry paper describing its target was later retracted. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semax or Dihexa?
Neither is universally "better" - the choice depends on your specific goals. Semax is typically used for cognitive purposes, while Dihexa is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semax and Dihexa be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semax and Dihexa together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.